The Marketing Authorization (ANDA) of budesonide capsule 3mg granted on Sep 28, 2017, which is also the first NADA granted by US FDA to Sciecure, is a great achievement that came from the unremiting endeavor of Beijing Sciecure subsidiary - US Sciecure Pharma.
Prev：Marketing Authorization (MA) of Aripiprazole Sciecure 10mg and 15mg orodispersible tablets are granted by UK MHRA
Next：Marketing Authorization(MA) of Celecoxib capsules100mg & 200mgare granted byPortugalNational Authority of Medicines and Health Products